huberman glp-1 What happens when people stop taking drugs? Mark Hyman, MD explains. | Andrew GLP-1 Insights | Ask Huberman

Although there was no significant effect on body weight, BMI, or truncal adiposity, there was a significant decrease in appetite scores and eating behavior [16]

Salade, et al

Indian patients with the thin-fat phenotype often experience disproportionately high improvements in waist circumference and metabolic markers even with modest overall weight loss, because GLP-1 preferentially targets the visceral fat that drives metabolic disease

It didnt respond

BPC-157 is interesting in this context because it doesnt just manage pain it may actually help repair damaged cartilage and soft tissue

Dose schedule with type 2 diabetes Retatrutide is being studied for type 2 diabetes in separate clinical trials